Stem cells for use in reducing the immune response following organ transplantation
AssigneeAmniotics AB
InventorsJan Talts, Sandra Lindstedt Ingemansson
Life of this patent
Estimating the term…
Abstract
The present invention relates to the mesenchymal stem cells and their use in modulating the immune response following transplantation.
Claims23
A method of modulating an immune response in a subject after tissue and/or organ transplantation comprising administering to said subject isolated term amniotic fluid (TAF) mesenchymal stem cells (MSCs) or a composition comprising isolated TAF MSCs.
2-24. (canceled)
A method of treating or inhibiting transplant rejection of a donor tissue and/or donor organ, graft dysfunction and/or graft versus host disease (GVHD) comprising administering to said subject isolated TAF MSCs or a composition comprising isolated TAF MSCs.
Dependencies are inferred from the claim text.